Galvanize is a biomedical platform company that develops proprietary pulsed electric field (PEF) technologies to selectively eliminate disease‑associated cells without thermal injury. Its integrated catheter and device systems enable minimally invasive, precision treatments for cardiac, pulmonary, oncologic, and vascular conditions, supported by a full clinical development pipeline and partnership model for hospitals and interventional physicians.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OFounders
Product
Problem
Current therapeutic options for many solid and vascular diseases rely on drugs or thermal ablation, which can lack precision, cause collateral tissue damage, and often require invasive procedures or prolonged treatment courses. This limits the ability to effectively target diseased cells while preserving healthy tissue, leading to suboptimal outcomes and higher healthcare costs.
Solution
Galvanize is a biomedical platform company that develops pulsed electric field (PEF) technologies designed to selectively target and eliminate disease‑associated cells without thermal injury. The company engineers proprietary energy delivery systems that create controlled electric fields to induce irreversible electroporation in targeted tissues. Galvanize validates each technology through rigorously designed clinical trials to demonstrate safety, efficacy, and reproducible outcomes. By partnering with physicians and healthcare systems, the company integrates its PEF platforms into existing treatment pathways, enabling minimally invasive, precise interventions across multiple therapeutic areas.
Target Audience
Primary customers are interventional physicians and surgical teams in hospitals and health‑system networks seeking minimally invasive, precision therapies for cardiac, pulmonary, oncologic, and vascular conditions.
Features
- Proprietary pulsed electric field generators that deliver precise, non‑thermal energy to induce irreversible electroporation in targeted cells
- Integrated catheter and device designs optimized for minimally invasive access to cardiac, pulmonary, oncologic, and vascular sites
- Real‑time monitoring and control algorithms that adjust field parameters to ensure selective cell targeting while sparing surrounding healthy tissue
- Scalable platform architecture that can be adapted for multiple disease indications and procedural workflows
- End‑to‑end clinical development pipeline, including Phase I/II trials with predefined safety and efficacy endpoints
- Regulatory‑focused development strategy with documented pathways for FDA 510(k) and de novo submissions across device classes
- Partnership model that provides training, data analytics, and support services to hospitals and physician groups for rapid adoption